Progressive retinal atrophy (PRA) is a prevalent inherited eye disorder causing gradual, irreversible blindness in dogs. Among the various types, the rough collie and smooth collie breeds are notably affected by the RCD2 variant of PRA. This guide covers RCD2 PRA, the dogs it impacts, and why genetic testing is vital to safeguard these breeds’ health through responsible breeding practices in the United States.
RCD2, or rod-cone dysplasia type 2, is a subtype of PRA characterized by the early degeneration of rods and cones—cells in the retina sensitive to light and color—which leads to rapid vision deterioration. Unlike other PRA forms that typically manifest symptoms after three years, signs of RCD2 may appear as early as six weeks of age. Affected pups commonly lose night vision around this time and progress to total blindness between 6 to 8 months.
In RCD2, rod cells deteriorate first, leading initially to night blindness. Subsequently, cone cell damage results in complete loss of sight. This swift progression highlights the importance for breeders and owners of these collie breeds to understand RCD2 thoroughly.
RCD2 primarily affects both rough and smooth collies. Dogs with partial ancestry from these breeds may carry the defective gene and unknowingly pass it along. In the United States, this inherited disease typically appears early, with puppies facing night vision challenges by six weeks and possible full blindness by a year old.
Without genetic screening, breeding carriers can inadvertently spread the condition, making testing essential in breeding programs nationwide.
RCD2 PRA is inherited in an autosomal recessive manner, meaning:
Understanding these inheritance patterns helps breeders avoid producing puppies with PRA RCD2.
The disease progresses quickly, and affected puppies usually show signs early, prompting owners and breeders to remove them from breeding programs. However, many healthy-looking dogs may be silent carriers of the mutation, passing it unknowingly if not tested.
Genetic testing identifies a dog’s status as clear, carrier, or affected. This information empowers American breeders to make responsible mating decisions, drastically lowering PRA RCD2 incidence in future litters.
A DNA sample is collected, usually via a cheek swab, by a veterinarian. The sample is then sent to accredited genetic testing labs specializing in canine hereditary conditions. In the U.S., reputable labs offering PRA RCD2 testing include OptiGen (University of Missouri), Animal Genetics (University of Pennsylvania), and Paw Print Genetics. Results typically return in one to two weeks, stating the dog's genetic status as clear, carrier, or affected.
To maintain the health and vitality of rough and smooth collies, American breeders should:
These practices help preserve the collie breeds’ legacy and reduce the chance of blindness in future generations.
For general information on PRA in dogs, please refer to trusted veterinary resources and breed clubs. If you're searching to find a rough collie puppy or a smooth collie puppy, seek out breeders who conduct thorough genetic testing for hereditary conditions like PRA RCD2 to ensure a healthy companion.
Genetic testing combined with responsible breeding decisions is key to preventing inherited blindness and safeguarding the future of beloved rough and smooth collie breeds in the USA.